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Background: Safe and effective use of digoxin in the hospitalized 
populations requires information about the drug’s pharmacokinetics 
and the influence of various factors on drug’s disposition. However, 
no attempts were made to link an individual’s digoxin requirements 
with nutritional status.  
Objectives: The main goal of this study is to estimate the population 
pharmacokinetics of digoxin and identify nutritional status that 
explains pharmacokinetic variability in hospitalized Korean patients. 
Methods: Routine therapeutic drug monitoring data from 106 patients 
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who received oral digoxin at Seoul National University Bundang 
Hospital were retrospectively collected. The pharmacokinetics of 
digoxin was analyzed with a one-compartment open pharmacokinetic 
model using Nonlinear Mixed Effects Modeling (NONMEM) and a 
multiple trough screen approach. 
Results: The effect of demographic characteristics, and biochemical 
and nutritional indices were explored. Estimates generated by 
NONMEM indicated that apparent clearance (CL/F) of digoxin was 
influenced by the renal function, serum potassium, age, and percent of 
ideal body weight (PIBW). These influences could be modeled by 
following equation CL/F (L/h) = 1.36× (CCR/50)1.580 × K0.835 × 0.055× 
(AGE/65) × (PIBW/100)0.403. The inter-individual variability (CV) for 
CL/F was 34.3% and the residual variability (SD) between observed 
and predicted concentrations was 0.225 µg/L. The median estimates 
from a bootstrap procedure were comparable and within 5% of the 
estimates from NONMEM. Correlation analysis with the validation 
group showed a linear correlation between observed and predicted 
values.  
Discussion: The use of this model in routine TDM requires that 
certain conditions be met that are consistent with the conditions of 
the sub-populations in the present study. Therefore, the authors 
advocate further studies to elucidate the effects of various nutritional 
status on digoxin pharmacokinetics.  
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Conclusion: The present study established important sources of 
variability in digoxin pharmacokinetics and showed the relationship 
between pharmacokinetic parameters and nutritional status in 
hospitalized Korean patients. 
 
Keywords : Digoxin, Nonlinear Mixed Effects Modeling, population 
             pharmacokinetics, NONMEM, nutritional status 
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Digoxin is one of the commonly prescribed cardiac medications and 
an integral part of the treatment for heart failure and atrial 
fibrillation.1 However, the drug is difficult to administer, because it 
lacks a clear relationship between the dose and desired effect. 
Furthermore, routine dosage of the drug can cause toxicity due to a 
narrow therapeutic index and inter-/intra-individual variability in its 
pharmacokinetics.1 Therefore, individualized dosage regimen of 
digoxin is of great significance. 
It is important to recognize how the pharmacokinetics of digoxin 
varies in hospitalized patients in order to administer the drug safely 
and effectively. It is also critical to understand the effect of various 
clinical factors on the pharmacokinetics of digoxin in performing 
therapeutic drug monitoring (TDM),2, 3 that improves patient care and 
contributes to decrease to suspected digoxin toxicity. Among various 
clinical factors, demographics have a critical impact on the 
pharmacokinetic parameters of digoxin and nutritional problems 
including malnutrition are highly prevalent in hospitalized patients. 
Especially, nutrition problems are related to increased morbidity, 
length of hospital stay, costs and mortality.4, 5 
Hanratty and associates show that the pharmacokinetics of digoxin is 
affected by aging-related changes including nutritional status such as 
body mass or weight.6 This contributes to the development of toxicity 
in older patients. Moreover, Korean population has less mean digoxin 
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dosage and concentration compared to other population7 and epidemic 
obesity or muscle mass is different between asian and western 
population.8 
Previously, the population pharmacokinetics of digoxin were 
examined using the computer program NONMEM, developed by Beal 
and Sheiner.9 Several studies have investigated various races-, and 
age-groups, and pediatric patients in an effort to identify important 
sources of pharmacokinetic variability of digoxin.10-12 But, no 
attempts were made in these studies to link an individual’s digoxin 
pharmacokinetics with nutritional status. Therefore, this study 
examines relationship between the digoxin pharmacokinetics and 
pathophysiological and nutritional status. The previous studies also 
didn’t explain the differences among various race estimates as well as 
models of digoxin population pharmacokinetics in Korean patients. 
The main purpose of this study is to estimate and identify influential 




































The usual oral adult maintenance dosage of digoxin administered as 
tablet is 0.125-0.5 mg once daily. Data sources (255 observations) of 
population group were retrospectively collected from 106 patients at 
Seoul National University Bundang Hospital (a 900-bed, tertiary care 
academic medical center in South Korea) who were administered a 
tablet form of digoxin (Digosin; CJ Pharmaceutical Co. Ltd, Korea). 
The patients were all hospitalized and under the supervision of 
medical and nursing staff such that the administration of treatment 
and compliance were standardized.13 Additionally, we analyzed 43 
samples (16 patients) as the validation group for a predictive 
performance study and the patient information is given in Table 1. We 
reconfirmed, from electronic medical records, basic information on 
the patients and pathologies from blood samples. The collected data 
were (1) demographic data; age, gender, total body weight and height, 
(2) clinical data; indication for digoxin, laboratory data of routine care 
(creatinine clearance, K; serum potassium, WBC; white blood cell, 
lymphocyte) (3) medication history; dosage regimen of digoxin, 
concomitant medications, date and time of administration, sampling 
time of digoxin (4) nutritional data; serum albumin, cholesterol, 
percentage of ideal body weight (PIBW), total lymphocyte count 
(TLC), nutritional risk index (NRI).  
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The percent of ideal body weight (PIBW) reflects chronic nutritional 
status more accurately than other nutritional factors.14 At the time of 
the hospital admission, the recent change in patients’ weight is more 
suitable to examine acute nutritional status.14 The NRI, used in the 
Veterans Administration Cooperative Group study of perioperative 
parenteral nutrition, stratified operative morbidity and mortality.15,16 
NRI = [1.519 × albumin (mg/dl)] + [41.7 × present/usual body weight 
(kg)]  
Derivation of NRI (score of > 100, no risk; 97.5 to 100, mild risk; 
83.5 to 97.5, moderate risk; 83.5, severe risk) is based on serum 
albumin and weight change, so NRI is a valid measure of health status 
and contains a nutritional dimension.16 Malnutrition leads to decline in 
immune function. TLC is calculated by multiplying the white blood cell 
count by percentage of lymphocytes and one of the clinical measures 
of immune function that have been used as nutritional screening or 
assessment parameters.5 The nutritional data used in the present 
study intended to reflect both acute and chronic nutritional status, 
severity of illness as well as the risk of malnutrition. 
The present study excluded patients who had any major disorders 
of the hepatic, gastrointestinal, or hematopoietic systems, exhibited 
fluctuating or rapidly deteriorating renal function,11 and who were 
taking drugs that may interact with digoxin (for example, amiodarone, 
quinidine, cholestyramine or phenytoin). This was done to eliminate 
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the effects of non-renal excretion, malabsorption of digoxin and 
misinterpretation of nutritional factor such as TLC. The digoxin 
concentrations for TDM were measured in terms of one trough level, 
based on the concentration of the steady state (chronic user or after 
10 doses at least) that has completed volume of distribution in order 
to ensure the accuracy of measurements. We kept reliable sampling 
points and excluded patients with uncertain sampling records. Also, 
multiple trough screen approach is applied to estimate the 
pharmacokinetic parameters of a population using sparse data 
collected during routine clinical care. We equally applied the criteria 
regarding the data collection between the population and validation 
group. 
The study was conducted in accordance with the Declaration of 
Helsinki and its amendments17 and was approved by the Institutional 
Review Board (IRB) of Seoul National University Bundang Hospital 
(B-1009-112-107). We submitted the waiver of informed consent for 
data collection and analyses according to HRPP (Human Research 
Protection Program) based on 45 CFR 46 subpart A 46.116. We didn’t 
have patients’ signed consents. However, our study was approved by 
IRB. IRB imposes a strict limitation on retrospective data collection 
without signed consent. Consequently, we were able to see only their 
clinical data but not individual information. The entire process about 
retrospective data collection was acceptable only after the 
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representative researcher had submitted a written declaration.  
The measurement of digoxin in serum was carried out by a TDx 
digoxin assay kit from Abbot Laboratories for fluorescence 
polarization immunoassay (FPIA). The minimum detectable 
concentration for digoxin was 0.2 µg/L, and the coefficients of 
variation (CV) both between runs and within runs were less than 10% 
for concentrations between 0.5 and 5.0 µg/L. 
 
Population Pharmacokinetic Model 
 
Population pharmacokinetic modeling was performed using the 
NONMEM program (Version VI) developed by Sheiner and Beal.18 The 
Xpose and Perl-speaks-NONMEM (PsN) modules were used for 
graphic and statistical model analysis.19, 20 The principle of the 
extended non-linear least squares was applied to estimate the 
population pharmacokinetic parameters using the patient’s sparse 
plasma concentration data, pathological factors, physiological factors 
and co-administration.21 A one-compartment pharmacokinetic model 
using the subroutines ADVAN2 and TRANS2 (first-order absorption) 
was used to fit the data.12 Data were parameterized in terms of 
apparent clearance (CL/F, L/h), apparent volume of distribution (Vd/F, 
L), and absorption rate constant (Ka, h-1). The absorption rate 
constant of digoxin can be calculated from plasma concentration 
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values 1 h after dosing.22 However, each patient contributed to only 
one data point and it was impossible to build an absorption model 
using the limited data,-; therefore, the model was simplified by fixing 
Ka to 1.63 h-1 based on values reported in the literature.22, 23 
The inter-individual variability was best explained by exponential 
error model according to the following equations: 
CL/Fij = TVCL* EXP(ηiCL) 
Vd/Fij = TVV* EXP(ηiVd) 
where CL/Fij is the jth true CL/F for ith individual, Vd/Fij is the jth true 
Vd/F for ith individual, TVCL is typical value of CL/F, TVV is typical 
value of Vd/F predicted by a regression model, and ηiCL, ηiVd are 
random variable distributed with zero means and respective variance 
of ω2CL and ω2Vd respectively. The residual (error) variability was also 
best explained by additive error model and can be expressed as 
follows: 
Cij = Cpredij + εij 
where Cij is the jth observed concentration for the ith individual, Cpredij 
is the digoxin concentration predicted by the pharmacokinetic model, 
and εij is a difference value between Cij and Cpredij and randomly 
distributed term of zero mean and variance σ2 which represented the 
residual intra-individual variability.24 This type of error is caused by 
influences such as assay variability, misspecification of the suggested 
pharmacokinetic model, and timing errors in drug administration or 
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blood sampling.10  
 
Data Analysis Procedure 
 
Initially, base regression analysis (without covariate) was applied to 
the data in order to develop a fixed-effect model. Ranges derived 
from the literature were used for initial estimates of digoxin 
pharmacokinetic parameters. Parameter-covariate relationships were 
initially explored by visual inspection and linear regression. The 
covariate model was established using a forward- 
inclusion/backward-elimination method incorporating a stepwise 
approach. Each covariate was added into the basic model and the 
change in objective function value (OFV) was considered for 
candidate covariate (preliminary screening phase). Next, the 
candidate covariates were sequentially added to the basic regression 
model, and the apparent influence of each covariate on digoxin 
disposition was determined based on the change OFV (forward 
stepwise fashion). The covariates screened were age, gender, weight, 
creatinine clearance (CCR), serum potassium, albumin, cholesterol, 
PIBW, TLC, NRI, and indication for digoxin. In order to identify 
potentially significant covariates, differences in OFV associated with 
a p-value of <0.05 (>3.84 for 1 degree of freedom) was required in 
the processes of stepwise modeling.13 The other factors were added 
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cumulatively to the reduction in OFV until there was no further 
reduction in the OFV. Then the backward elimination process was 
used to identify the significant covariates for the final model. The 
imprecision (uncertainty) in parameter estimation of the model was 
calculated by dividing the standard error of each by its value (RSE%, 
relative standard error) and expressed as a percentage of coefficient 
of variation (CV%). Scatterplots of observed versus predicted 
concentrations (PRED) and individual concentrations (IPRED) were 




 Model evaluation and validation are important components in 
determining model appropriateness.13 Therefore, model qualification 
was conducted to assess the model capacity to predict the individual 
observations. The bootstrap method was applied as an internal 
validation approach to assess the stability of the final parameter 
estimates and to confirm the robustness of the final model. It was 
performed with the assistance of PsN (Perl-speak-NONMEM; 
http://psn.sourceforge.net). The final model was used to repeatedly fit 
the 1000 bootstrap data sets, and parameters were estimated for each 
data set.25 The median and 95% confidence interval were calculated 
for each pharmacokinetic parameter.  
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Visual predictive check (VPC) as diagnostic plot was also assessed 
to confirm model performance. The final model was assessed by an 
inspection of standard diagnostic plots of observed concentration 
versus population and individual predicted concentration and separate 
plots of weighted residual versus model-predicted concentration.26 
After the population model was determined, clinical information of the 
validated group were input into the NONMEM program to estimate the 
individually predicted values of the serum concentrations and 
compared with measured values. The linear relation was also 








































The demographic characteristics of the study population are 
summarized in Table 1. There were 106 patients in the study, with 
the mean age being 73 years, and mean dosage being 0.133 ± 0.053 
mg/day. A total of 255 blood samples were analyzed, yielding a 
digoxin concentration of 0.866 ± 0.341 µg/L (mean ± SD). 
Figure 1 shows the correlation between daily dose and serum 
concentration of digoxin. For a given daily dose, the steady-state 
serum concentration of digoxin has a wide range of level and the poor 
correlation (r = 0.136) implies that it is impossible to predict serum 
concentrations on the basis of the daily digoxin dose alone. Therefore, 
the authors applied population pharmacokinetic modeling using 
NONMEM, which is a better approach for predicting drug 
concentration and optimizing the dosage regimen of digoxin. 
We determined values of sigma (σ2), omega (ω2), theta (θ) and error 
model in order to explain the best structural (base) model. The 
exponential error model was suitable to explain inter-individual 
variability and the additive error model was suitable to explain 
residual variability in Vd/F and CL/F. There were many indicators of 
the improvement of fit resulting from the addition of certain 
parameters to the model- including a decrease in the standard error 
of the estimates, reduction in variability, reduction in weighted 
residuals, uniformity of physiological plausibility, and the scatterplot 
of weighted residuals versus predicted concentrations. The base 
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model of Vd/F was markedly affected by CCR, weight, serum 
potassium, age, and cholesterol and the base model of CL/F was 
markedly affected by CCR, serum potassium (K), age, PIBW, TLC, and 
albumin. However, when these factors were stacked, Vd/F and CL/F 
were significantly affected by weight and the combination of CCR, K, 
age, PIBW. NONMEM analysis steps of the covariates are summarized 
in Table 2. The population estimates for Vd/F and CL/F were 735 L, 
1.36 L/h, respectively. The inter-individual variability (CV) was 56.8% 
for Vd/F and 34.3% for CL/F. The residual variability (SD) between 
the observed and predicted concentrations was 0.225 µg/L. The final 
regression model is Ka = 1.63 (h-1, fixed), Vd/F = θ2 × (weight/55)θ4 
(L), CL/F = θ3 × (CCR/50)θ5 × Kθ6 × θ7 × (AGE/65) × (PIBW/100)θ8 (L/h). 
The observed versus population predicted concentrations (PRED) 
and individual predicted concentrations (IPRED) of final model were 
showed as scatterplot in Figure 2. The final model was improved, as 
the identity line of the scatterplot appeared together with a narrow 
gap and the number of points that were far from the identity line was 
reduced. Figure 3 shows weighted residual versus predicted 
concentration obtained from the base model was compared with the 
final model. In the scatterplot of the final model, the large positive 
residuals were cleared. These observations suggest that the resultant 
model fit the observed data well. Additionally, we assessed VPC to 
confirm model performance (Figure 4). Most of the observed 
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concentrations fall within the 90% predicted intervals obtained from 
the stimulated data represented by the shaded area. 
The parameter estimates of the final model using the original data 
set, the median parameter estimates, and the 95% confidence 
intervals obtained from bootstrap replications with successful runs 
are shown in Table 3. The median parameter estimates were within 
20% of those obtained with the original data set. The accuracy of the 
pharmacokinetic model was acceptable on the basis of the reasonably 
close agreement between corresponding pairs of bootstrap samples 
and the final model parameters. 
Clinical information of the validation group is presented in Table 1. 
The individual values of digoxin steady-state serum concentration 
from the validation group had been predicted by the established final 
model. Correlation analysis showed a linear correlation between 
observations and predicted values (y =0.681x+0.292, r = 0.743, p < 
0.001), indicating that the model may be helpful in clinical practice to 

































To our knowledge, this is the first study to identify the influence of 
nutritional and demographic variables on pharmacokinetics of digoxin 
in hospitalized Korean patients by using NONMEM. Estimates 
generated by NONMEM indicated that digoxin CL/F (L/h) was 
influenced by CCR (ml/min), serum potassium (mmol/L), age (years), 
and PIBW (%). The relative influence of each variable can be 
represented by the following equation: CL/F = 1.36 × (CCR/50)1.580 × 
K0.835 × 0.055× (AGE/65) × (PIBW/100)0.403. Vd/F (L) can be 
represented by the following equation: Vd/F = 735× (weight/55)0.902. 
Digoxin exhibits a narrow therapeutic index and large inter/intra-
patient variability in disposition, which requires that doses be 
carefully adjusted per an individual patient’s needs, in order to 
minimize digoxin toxicity.27 It is important to understand the effect of 
various clinical factors on the pharmacokinetics of digoxin. Both 
demographic factors and nutritional status considerably influences the 
absorption, plasma protein binding, distribution, biotransformation and 
excretion of drugs.28, 29 Albumin, NRI, and TLC were not significantly 
associated with change in digoxin pharmacokinetic parameters in the 
present study. Malnutrition is a progressive condition and evaluation 
of an influence of malnutrition on drug pharmacokinetics is 
confounded by issues of time. These nutritional factors have been 
referred to as acute-phase state and are decreased in serum 
concentration in response to acute inflammation, liver and renal 
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function, hydration and blood loss.5, 30 In comparison to population 
group, validation group shows significant difference in acute 
nutritional factors such as albumin and NRI. Because acute nutritional 
factors can be altered based on clinical signs and severity of disease, 
they are not suitable to explain the impact of the nutrition on digoxin 
PK in acute phase. Therefore, acute-phase nutritional factors have 
limitation in explaining to influence on pharmacokinetics of digoxin in 
hospitalized patients. 
About half of the total body digoxin load is bound to skeletal muscle, 
whereas only 1% is in circulation.29 When analyzed in tissue obtained 
intraoperatively and postmortem, a high amount of digoxin was found 
distributed in muscle, with lesser amounts in plasma and other body 
constituents.31 Therefore, small changes in the fraction bound to 
skeletal muscle could profoundly affect the concentration of the drug 
in serum. The somatic protein status as represented the weight is 
equivalent to the skeletal muscle mass that declines in response to 
malnutrition or catabolic conditions.32 We analyzed the effect of PIBW, 
as an indication of chronic nutritional status and change of patients. 
PIBW is an appropriate factor for use in investigation of the 
relationship between digoxin’s CL/F and nutrition, because being 
chronically underweight has a substantial impact on digoxin’s CL/F. 
PIBW may also indicate muscle wasting, an effect of muscle mass 
reduction, as well providing an accurate measurement of renal 
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function. Ferrara et al.33 studied a model based on body composition 
and bioelectric impedance analysis (BIA) to predict digoxin kinetics in 
the elderly. Their findings indicated that digoxin levels, calculated via 
BIA, may be sufficiently reliable in the majority of patients, because 
exact plasma creatinine monitoring was predicted by measuring 
variability of muscle wasting. Asian populations are lean when 
compared with western population.8 Also, Yoon et al.34 studied the 
epidemic obesity in Asia, this showed the prevalence of overweight 
and obese adults between Korea and USA (27.4%:34% and 3.2%:30%, 
respectively).35 This is also related to the fact that PIBW is the 
influence factor on digoxin pharmacokinetics in Korean. 
The final regression model suggests that clearance of digoxin is 
associated by CCR. In other studies, decreases in the volume of 
distribution of digoxin in patients with renal impairment have been 
reported.36 A study by Reuning et al.37 suggested that possible 
explanations for the decrease in the volume of distribution of digoxin 
in cases of renal failure include: reduction of the tissue mass (e.g., 
skeletal muscle), and decrease in digoxin binding to other organs than 
skeletal muscle.38-40 However, Jogestrand and Ericsson38 found that 
the ratio of the concentration of digoxin in biopsied skeletal muscle to 
its serum concentration did not differ significantly between patients 
with renal failure and subjects with normal renal function. Reduced 
body tissue mass due to chronic renal failure was evidently not an 
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important factor. In the present study, CCR also has not significant 
effect on the Vd/F of digoxin. 
It is widely accepted that age influences digoxin distribution.6 This is 
mainly because of the influence of lean body mass, which decreases 
by approximately 20% from the age of 20 years to the age of 70 
years.6 A loss of skeletal muscle is common in the elderly.41 The 
volume of distribution of digoxin reduces with age, which may result 
in its higher serum concentrations. However, our study does not show 
an effect of age on Vd/F, and only shows covariation of CL/F with age, 
possibly due to the reduction of aging-associated glomerular filtration. 
Several previous studies have suggested that congestive heart 
failure (CHF) is an important factor in digoxin clearance estimation.13, 
26 In adults, Sheiner et al.9 found that digoxin clearance in patients 
with CHF was significantly lower than that in patients without CHF. In 
subsequent studies, it was reported that digoxin clearance was 
reduced by 19% and 11.8% in adults and infants with CHF, 
respectively.13, 42 However, in the present study, no effect of CHF on 
CL/F of digoxin is apparent. 
Some reports have suggested that when digoxin is taken orally with 
calcium-channel blockers (CCBs), such as verapamil and diltiazem, 
and spironolactone (SPI), the serum concentration of digoxin 
increases, potentially resulting in an increased risk of digoxin 
toxicity.6, 11 However, in the present study, parallel treatment with 
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these drugs is not common and do not affect CL/F of digoxin. 
Table 4 shows various population estimates and models of digoxin 
population pharmacokinetics. The differences apparent therein may 
be related to population sizes, the length of disease course or its 
severity, and the methods of population analysis. Further, p-
glycoprotein (P-gp), the expression product of the human multidrug 
resistance 1 (MDR1) gene, is an important factor in the disposition of 
many drugs.44 It is possible that in patients not adhering to the data 
predicted by the model there may be alterations in digoxin handling 
due, for example, to P-gp polymorphism, a variable resulting in more 
than 30% variability in steady-state digoxin levels.45 There are 50 
single nucleotide polymorphism (SNPs) in the MDR1 gene, and the 
exon 26 C3435T SNP is associated with a change in the oral 
absorption of digoxin.45, 46 The distribution of C3435T polymorphism 
is significantly influenced by ethnicity. There is no study about 
genetic metabolic efficiency on digoxin serum concentration in Korea 
patients yet. However, there are other studies associated with MDR1 
gene polymorphism presented MDR1 C3435T polymorphism in 
Korean. They showed C as the dominant allele.47, 48 The causative 
molecular genetic mechanism of the effects of this polymorphism is 
unknown.45 C3435T polymorphism in Korean helps explaining the 
observed differences with other studies, but the exact causes of the 
above CL/F differences require further exploration.  
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Conventional compartmental analysis of digoxin levels has reported 
a two-compartment model in healthy adults.49 However, population 
analysis of sparse data has found a one-compartment model adequate 
for explaining the pharmacokinetics of digoxin.9 Because of the 
limited sampling strategy used in the TDM laboratory, this study also 
decided the performance of population pharmacokinetic analysis in 
the light of a multiple-trough screening approach to digoxin 
concentration. Furthermore, one-compartment model was easy 
application for TDM service in the clinical practice. 
No models of digoxin pharmacokinetics have suggested a 
relationship with nutritional status. Our study may explain the effect 
of chronic nutritional status on the pharmacokinetics of digoxin. This 
also explains the reason for lower mean digoxin dosage and 
concentration in Korean population. Multiple factors should still be 
considered with regard to digoxin dosage adjustment, such as other 
drug interactions, effects of absorption in gastrointestinal disease, 
and other intensive care environments exist. Also, MDR1 C3435T 
polymorphism in Korean needs to be considered in order to prove the 
effect on digoxin pharmacokinetics more precisely. In addition to 
monitoring of digoxin concentration, each patient’s clinical status and 
drug toxicity should also be monitored. Its pharmacologic and clinical 
effects correlate not with serum digoxin concentration but with those 
in the peripheral nonserum compartment.7 Our study did not analyze 
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the peripheral concentration. Thus, the use of this model in routine 
TDM requires that certain conditions be met that are consistent with 
the conditions of the sub-populations in the present study. The 
authors advocate further studies to elucidate the effects of various 
nutritional parameters on digoxin pharmacokinetics and to validate 












































Using NONMEM, estimates of digoxin population pharmacokinetics 
were derived from a population of hospitalized Korean patients for the 
first time. Renal function, serum potassium, age, and PIBW were 
identified as significant covariates for digoxin CL/F. The present 
study established important sources of variability in digoxin 
pharmacokinetics and showed the relationship between 
pharmacokinetic parameters and nutritional status in hospitalized 

















































Number of patients 106 16  
Number of samples  255 43  
Samples per patients (mean, range) 2.40 (1-10) 2.68 (1-8)  
Digoxin dose (mg/day) 0.133 ± 0.053 0.113 ± 0.066 0.057 
Serum digoxin concentration (µg/L) 0.866 ± 0.341 0.693 ± 0.380 0.003 
Gender (n(%))    
    Male  58 (54.7) 8 (50.0)  
    Female  48 (45.3) 8 (50.0)  
Age (years) 72.8 ± 13.0 70.1  ± 12.5 0.252 
Weight (kg) 57.3 ± 12.0 54.2  ± 12.9 0.113 
Percent of ideal body weight (%) 99.7 ± 17.0 103.0 ± 21.8 0.328 
Indications (n(%))    
    Artrial fibrilation 55 (51.9) 13 (81.2)  
    Heart failure 12 (11.3) 2  (12.5)  
    Othersb 39 (36.8) 1  (6.3)  
Concomitant medications (n(%))    
    Calcium-channel blockers 19 (17.9) 3  (18.7)  
    Spironolactone  3  (2.8) 0  (0)  
Creatinine clearancec (ml/min) 51.5 ± 24.6 42.9 ± 27.6 0.065 
Serum potassium (mmol/L) 4.28 ± 0.57 4.05 ± 0.57 0.023 
Serum albumin (g/dl) 3.41 ± 0.54 2.87 ± 0.45 < 0.001 
Serum cholesterol (mg/dl) 148.3 ± 40.5 126.1 ± 34.8 0.002 
TLCd (cells/mm3) 1536.4 ± 921.4 1159.9 ± 517.1 0.013 
NRIe  92.5 ± 8.4 72.9 ± 6.8 < 0.001 
a Mean ± standard deviation unless otherwise stated 
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b Cor-pulmonale, myocardial infarction, ventricular septal defect, post-operation 
c Estimating creatinine clearance (CLCR) by the Cockcroft and Gault method
 
d Total lymphocyte count  = [white blood cell × % lymphocyte]/ 100 


















Table 2. Summary of the covariate model results by forward and 
 backward stepwise 
Model OFV ∆OFV 
p-
value 
Basic model -250.134   
Vd/F= 588*(CCR/50)0.845*(ABW/60)0.686 
CL/F= 3.49*(CCR/50)0.678 
-282.084 31.95 <0.001 
Vd/F= 535*(CCR/50)0.922*(ABW/60)0.520 
CL/F= 0.139*(CCR/50)0.737*PIBW0.700 
-286.566 36.43 <0.001 
Vd/F= 607*(CCR/50)0.640*(ABW/60)0.840 
CL/F= 0.206*(CCR/50)1.190*K0.674 
-334.887 84.75 <0.001 
Vd/F= 822*(ABW/60)0.975 
CL/F= 4.98*(CCR/50)1.608*K0.861*0.013*(AGE/65) 




-353.167 103.03 <0.001 
Vd/F, CL/F = volume of distribution, clearance, where F is bioavailability; OFV = 
objective function value; ∆OFV = decrease in OFV; CCR = creatinine clearance; ABW 








Table 3. Population pharmacokinetic parameters from final model and  
bootstrap validation 
Parameter 





SE Median 95% CI 
Pharmacokinetic parameters 
Ka (θ1) 1.63  (fixed)     
Vd/F (θ2) 735  (12.91) 94.9 724 453,919 -1.5 
Effect of ABW (θ4) 0.902 (54.21) 0.489 0.917 0.138,1.920 1.6 
CL/F (θ3) 1.36  (23.68) 0.322 1.410 0.836,2.278 3.5 
Effect of CCR (θ5) 1.580 (34.68) 0.548 1.590 0.521,2.310 0.6 
Effect of K (θ6) 0.835 (21.44) 0.179 0.815 0.550,1.050 -2.4 
Effect of AGE (θ7) 0.055 (51.74) 0.028 0.056 0.033,0.092 3.1 
Effect of PIBW 
(θ8) 
0.403 (90.82) 0.366 0.509 0.030,0.981 20.7 
Interindividual variability (%) 
Vd/F (ωVd/F) 56.83 (37.50) 33.3 59.2 21.7,91.0 3.9 
CL/F (ωCL/F) 34.26 (24.32) 16.6 33.6 22.7,40.2 -2.0 
Residual variability (SD, µg/L) 
Additive error (σ) 0.225 0.091 0.218 0.172,0.255 -3.2 
Ka (hr-1) = absorption rate constant; Vd/F (L), CL/F (L/hr) = volume of distribution, clearance, 
where F is bioavailability; CCR = creatinine clearance; ABW = actual body weight; PIBW = 
percent of ideal body weight; K = serum potassium; %RSE = percent of relative standard error 
(standard error/estimate × 100); SE = standard error; CI = 2.5th and 97.5th percentiles of 
bootstrap distributing of parameter estimates; Difference (%) = (bootstrap median value – 






Table 4. Previously documented methods for estimating digoxin  
population pharmacokinetic parameters in adults 
Sheiner et al.; 1-compartment model9 
CL (L/h) = 0.06 × CCR + 0.05 × TBW for CHF absent 
CL (L/h) = 0.053 × CCR + 0.02 ×TBW for CHF present 
Vd (L) = 3.12 × CCR + 3.84 × TBW 
F = 0.6 
 
Nagaraja et al.; 1-compartment model43 
CL (L/h) = 0.053 × CCR + 2.06 
Vd (L) = 6.63 × CCR + 10.82 × TBW -343 
Ka (h-1) = 0.546 – 0.103 × drug – 0.092 × sex 
 
Yukawa et al.; 2-compartment model11 
CL (L/h) = (0.036 × TBW + 0.112 × CCR) × 0.77SPI × 0.784CCB 
V1 = 1.83 L/kg, V2 = 22.6 L/kg, Q = 0.629 L/kg 
 
Xiao-dan et al.; 1-compartment model23 
CL/F (L/h) = 5.9 × [1- 0.412×SPI] × [1- 0.0101×(TBW-62.9)]  
× [1- 0.0012×(CCR-126.8)] 
 
Yukawa et al.; 1-compartment model13 
CL/F (L/h) = 0.588 × TBW0.189 × SCr-0.163 × (AGE/65)-0.152 × 0.957CCB × 0.941CHF  
× 0.965sex × Ctrough
-0.180 
CCR = creatinine clearance; TBW = total body weight; CHF = 1 for presence of 
congestive heart failure; drug = 0 for no, 1 for yes; sex = 0 for male, 1 for female; 
SPI = 1 for combination with spironolactone; CCB = 1 for combination with calcium-














































Figure 2. The observed versus population predicted concentrations (PRED)- 
upper and individual predicted concentrations (IPRED)-lower of  




Figure 3. Comparison of scatterplot of weight residuals versus predicted  







Figure 4. Visual Predictive Check of final model.  
The solid red line represents the median observed concentration, and the 
semitransparent dark-green field represents a 95% confidence interval for 
the median. The observed 5% and 95% percentiles are presented with 
dashed red lines, and the 95% confidence intervals for the corresponding 
model predicted percentiles are shown as semitransparent dark-green. The 
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The Effect of Nutritional Factors on Volume of Distribution of Digoxin 
in Korean Adult Patients 
;A Population Pharmacokinetics Analysis Using Nonlinear Mixed-Effect 
Modeling 
 





Optimal use of digoxin in the malnourished populations requires information 
about the drug’s pharmacokinetics and the influence of various factors on 
drug’s disposition. However, because of sampling restrictions, it are not 
conducted pharmacokinetic studies of digoxin according to various 
nutritional status and in malnourished patients. The main goal of this study is 
to estimate  and identify influence of nutritional status on digoxin 
pharmacokinetic parameters in Korean patients. Data sources (287 
observations) were retrospectively collected from 108 patients receiving 
oral digoxin in Seoul National University Bundang Hospital between January, 
2008 and December, 2009, using routine therapeutic drug monitoring data. 
The pharmacokinetics of digoxin was analyzed with a one-compartment 
open pharmacokinetic model using Nonlinear Mixed Effects Modeling 
(NONMEM). We evaluated the degree of malnutrition and nutritional risk 
more specifically by assuming there is a relationship between digoxin’s Vd 
and skeletal muscle reduction. Estimates generated by NONMEM indicated 
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that the volume of distribution (Vd) of digoxin was influenced by the 
nutritional factors such as albumin, NRI (nutritional risk index). These 
influences could be modelled by equation CL = 5960*(creatinine 
clearance/59) 0.741, Vd = 688000*e 0.0759 * albumin. The interindividual and 
intraindividual variability for Vd were 49.5%, 23.74% as estimated coefficient 
variation. The present study established important sources of variability in 
digoxin pharmacokinetics. Clinical application of this model may help 
calculate digoxin dose requirements according to nutritional status affecting 





















Digoxin is one of commonly prescribed cardiac medications as an integral 
part of the treatment for heart failure and atrial fibrillation.1 However, 
because digoxin has a narrow therapeutic index and inter-/intra-individual 
variability in its pharmacokinetics1, it is a difficult drug to administer. 
Digoxin toxicity is well recognized.2,3 Although the incidence has been 
decreased to 2-5% in recent studies,2,4 digoxin has been considered still as a 
common cause for patient’s emergency room visits and long-term hospital 
stay.5 
Because of the lack of a clear relationship between the digoxin dose and the 
desired effect, serum digoxin level is the most widely used parameter in 
routine therapeutic drug monitoring.6  It improves patient care and 
contributes to decrease the suspected digoxin toxicity.7 It is therefore 
important to understand how the pharmacokinetics of digoxin may be altered 
in the hospitalized patients.  
Malnutrition is highly prevalent in hospitalized patients and related to 
increased morbidity, mortality, length of hospital stay and costs.8,9 We 
clinically experienced that pharmacokinetic parameters and concentration of 
digoxin were unpredictable in malnourished or serious ill patients than other 
hospitalized patients. The overall apparent distribution of digoxin to various 
organs and tissues appears to be largely related to the body distribution.1,10 
Skeletal muscle-bound digoxin appears to account for about 50% of apparent 
digoxin in the body. Accordingly, small variations in the occupancy of 
digitalis binding sites in skeletal muscle can influence the serum 
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concentrations available for binding to the heart. Also, the somatic protein 
status as represented the weight is equivalent to the skeletal muscle mass 
which declines in response to malnutrition or catabolic conditions.11 We have 
now examined the pharmacokinetics of digoxin with nutritional factors and 
how the degree of malnutrition or nutritional risk may affect the drug’s 
pharmacokinetics more specifically by assuming there is a relationship 
between volume of distribution (Vd) of digoxin and skeletal muscle reduction. 
Previously, the population pharmacokinetics of digoxin were examined using 
the computer program NONMEM, developed by Beal and Sheiner.12 Various 
race, old and pediatric group were targeted in several studies for explaining 
important source of variability.13-15 However, at that time, no attempt had 
been made to link the relationships between individual digoxin requirements 
and nutritional status. Therefore, the main goal of this study was to estimate 
and identify the influence of nutritional factors on pharmacokinetic 







Data sources (287 observations) were retrospectively collected from 108 
patients in Seoul National University Bundang Hospital (a 900-bed, tertiary 
care academic medical center in South Korea) between January, 2008 and 
December, 2009, who were administered a tablet form of digoxin (Digosin; 
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CJ Pharmaceutical Co. Ltd, Korea). The patients were all hospitalized and 
under the supervision of medical and nursing staff such that the 
administration of treatment and compliance were standardized. We 
reconfirmed, from electronic medical records, basic information on the 
patients and pathologies from blood samples. The collected data were (1) 
demographic data; age, gender, total body weight and height, (2) clinical data; 
indication for digoxin, laboratory data of routine care (creatinine clearance, 
serum potassium, WBC; white blood cell, lymphocyte) (3) medication history; 
dosage regimen of digoxin, concomitant medications, date and time of 
administration (4) nutritional data; serum albumin, cholesterol, percentage of 
ideal body weight (PIBW), total lymphocyte count (TLC), nutritional risk 
index (NRI).  
Albumin has been used to assess nutritional status, specifically protein 
nutriture. Despite considerable published information to the contrary, 
albumin has been assumed to reflect a reservoir of protein in conditions of 
adequate nutrition and a deficit of protein in conditions of inadequate 
nutrition. Decreased albumin levels correlate with poor clinical outcomes, 
increased length of stay, increased risk for complication, and death. 
Anthropometric measurements such as height and weight are the most useful 
way to assess changes in nutritional status of an individual in the clinical 
setting.
16 Especially, weight is one of the best parameters for evaluating a 
change in nutritional status when change from usual weight of an individual 
is quantified. The NRI, used in the Veterans Administration Cooperative 
Group study of perioperative parenteral nutrition, stratified operative 
morbidity and mortality using serum albumin and the ratio of current weight 
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to usual weight.17,18 Comparison of a patient’s current weight during the 
course of admission to their usual weight before admission is generally more 
useful than comparing current weight to an “ideal” or desirable weight.16 
NRI= [1.519×albumin(mg/dl)] + [41.7×present/usual body weight(kg)]  
NRI score of > 100 indicates no risk; 97.5 to 100, mild risk; 83.5 to 97.5, 
moderate risk; 83.5, severe risk. Derivation of NRI is based on serum 
albumin and weight change, so NRI is a valid measure of health status and 
contains a nutritional dimension.18 Malnutrition leads to decline in immune 
function. TLC is calculated by multiplying the white blood cell count by 
percentage of lymphocytes and one of the clinical measures of immune 
function that have been used as nutritional screening or assessment 
parameters.9 Thus, the nutritional data chosen in present study intend to 
reflect the various nutritional status, severity of illness and risk of 
malnutrition. 
There were excluded patients who have any major disorders of the hepatic 
or gastrointestinal or hematopoietic systems, or with fluctuating or rapidly 
deteriorating renal function and exhibit interactions with digoxin (for 
example, amiodarone, quinidine, cholestyramine or phenytoin). This is to 
eliminate the effects of the non-renal excretion, malabsorption of digoxin 
and misinterpretation of nutritional factor such as TLC. The samples were 
concentrations for therapeutic drug monitoring measured as one trough level. 
It was based on the concentration of the steady state (chronic user or after 
10 doses at least) that has completed distribution in order to ensure the 
measurement accuracy. The present study was approved by the IRB 
(Institutional Review Board of the Seoul National University Bundang 
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Hospital) about the data collections and analysis. (2010. 10.12 B-1009-112-
107) 
The measurement of digoxin in serum was carried out by a TDx digoxin 
assay kit from Abbot Laboratories for fluorescence polarization 
immunoassay (FPIA). The minimum detectable concentration for digoxin was 
0.2 ng/ml, and the coefficients of variation both between runs and within 
runs were less than 10% for concentrations between 0.5 and 5.0 ng/ml. 
 
Population Pharmacokinetic Model 
 
Population pharmacokinetic modeling was performed by using NONMEM 
program (Version VI) developed by Sheiner and Beal. Pharmacokinetic 
parameters were estimated by using the first-order estimation method with 
the POSTHOC option. Because of the sparse nature of the data, a one-
compartment pharmacokinetic model with using the subroutines ADVAN2 
and TRANS2 (first-order absorption) was performed to fit the data.15 Data 
was parameterized in terms of clearance (CL), volume of distribution (Vd), 
and absorption rate constant (Ka). Because each patient contributed to only 
one data point and it was impossible to build an absorption model by the 
limited data, the model was simplified by fixing Ka to 0.7 h-1 based on 
literature values.19 
The initial program run computed an overall population analysis of 
pharmacokinetic parameters and minimum value of the objective function. 
The interindividual variability was best explained by exponential error model 
according to the following equations: 
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CLij = TVCL*EXP(ηiCL) 
Vdij = TVV*EXP(ηiVd) 
where CLij is the jth true CL for ith individual, Vdij is the jth true Vd for ith 
individual, TVCL is typical value of CL, TVV is typical value of Vd predicted 
by a regression model, and ηiCL, ηiVd are random variable distributed with zero 
means and respective variance of ω2CL and ω2Vd respectively. The residual 
(error) variability was also best explained by additive error model and can 
be expressed as follows: 
Cij = Cpredij + εij 
where Cij is the jth observed concentration for the ith individual, Cpredij is the 
digoxin concentration predicted by the pharmacokinetic model, and εij is a 
difference value between Cij  and Cpredij and randomly distributed term of zero 
mean and variance σ2 which represented the residual intraindividual 
variability. This type of error is caused by influences such as assay 
variability, misspecification of the suggested pharmacokinetic model, and 
timing errors in drug administration or blood sampling. 
 
Data Analysis Procedure 
 
In the first step, the data were used to develop the basic regression model 
(without covariate) for fixed effect model. Literature ranges were used for 
initial estimates of digoxin pharmacokinetic parameters. Then each covariate 
was added into the basic model and the change in objective function value 
(OFV) was considered for candidate covariate (preliminary screening phase). 
Next step, the candidate covariate was added to the basic regression model, 
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in turn, and the apparent influence of covariate on digoxin disposition was 
observed by the changing of the OFV (forward stepwise fashion). Covariates 
screened were age, gender, weight, creatinine clearance (CCR), serum 
potassium, albumin, cholesterol, PIBW, TLC, NRI. The difference between 
OFVs for a model containing n covariates and that containing n-1 covariates 
by more than 10.83 (χ2 distribution, p< 0.001; 1 degree of freedom) was 
considered to be significant and added to the model. The other factors were 
added cumulatively to the reduction in OFV from the preliminary screening 
phase until there was no further reduction in the OFV. The imprecision 
(uncertainty) in parameter estimation of the model was calculated by dividing 
the standard error of each by its value and expressed as a percentage of 




 Model evaluation and validation are important components in determining 
model appropriateness. Therefore, model qualification was conducted to 
assess the model capacity to predict the individual observations. A scatter 
distribution of the observed concentration values against the predicted 
values was plotted. The base structural model and final model were validated 
by comparison with the data from validation data set. The bootstrap method 
was applied as an internal validation approach to assess the stability of the 
final parameter estimates and to confirm the robustness of the final model. It 
was performed with the assistance of PSN (Perl-Speak-NONMEM; 
http://psn.sourceforge.net). The final model was used to repeatedly fit the 
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1000 bootstrap data sets, and parameters were estimated for each data set. 
The median and 95% confidence interval were calculated for each 





The demographic data of the patients are presented in Table 1. The number 
of patient was 108 and the mean age was 73 years, mean dosage was 0.135 
± 0.054 (mg/day). The number of old age patients, defined as older than 65 
years old, was 89. Out of 108, 36 patients had heart failure and 56 of them 
had atrial fibrillation. A total of 287 blood samples were provided, with a 
mean ± SD digoxin concentration of 0.859 ± 0.384 mcg/L. Nutritional status 
of study subjects was evenly distributed, based on data of serum albumin, 
cholesterol, PIBW, NRI.  
Figure 1 shows the correlation between daily dose and serum concentration 
of digoxin. For a given daily dose, the steady-state serum concentration of 
digoxin has a wide range of level and the poor correlation (R=0.1315) implies 
that it is impossible to predict serum concentrations on the basis of the daily 
digoxin dose alone. Therefore, we decided to apply the population 
pharmacokinetic modeling using NONMEM, which is a better approach to 
predict drug concentration and optimize dosage regimen of digoxin. 
We determined values of sigma, theta and error model in order to explain the 
best structural (base) model. We chose a statistical regression model that 
could significantly reduce the objective function value (OFV) through the 
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process of trial and error. Table 2 presents NONMEM output of base model. 
The exponential error model was suitable to explain inter-individual 
variability and the additive error model was suitable to explain residual 
variability in Vd and CL. The estimated coefficient of variation was 40% and 
52.2% in Vd and CL respectively. 
As a preliminary analysis, we utilized covariates modeling that is presented 
in Table 3. The model was constructed by including covariates such as age, 
creatinine clearance (CCR), weight, percentage of ideal body weight, albumin, 
NRI, TLC, cholesterol, serum potassium, sex in the base model. It was also 
analyzed the relationship between those covariate and the pharmacokinetic 
parameters. We found out that estimate of CL was improved dramatically by 
inserting CCR in centered power model. Vd was improved significantly with 
only CCR though OFV was minimized with albumin, NRI, creatinine clearance 
in power, proportional and exponential model (table 3). Other covariates 
failed to reduce significant OFV or estimate the standard error in modeling 
of Vd and CL. 
Table 4 shows the combination modeling of Vd and CL by continous variable 
analysis. We inserted NRI, albumin, CCR on Vd and CCR on CL and OFV was 
reduced by more than 10.83 (χ2, p<0.001, 1 degree of freedom) from the 
base model. Parameter estimation was also optimized from FO to FOCE 
(first-order conditional estimation). Compared to the base model, the 
albumin, NRI, creatinine clearance turned out to be significant factors to 
explain the variability of digoxin pharmacokinetics. However, both albumin 
and NRI didn’t reduce RSE of Vd as much as we expected. The reason was 
that this study didn’t only include full pharmacokinetic data but also used 
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clinical therapeutic drug monitoring data. Also, theta value of NRI was 
beyond the scope of acceptable clinical range. Creatinine clearance (CCR) 
reduced RSE of Vd and CL in comparison with the base model and obtained 
the reliability. However, CCR’s result also had limitations to explain the Vd 
and CL at the same time as a single factor because of the correlation in Vd 
and CL (correlation matrix of estimate = -0.0319) as showed on NONMEM 
results. Therefore, the relationship between nutritional covariates and 
volume of distribution was suitable for being described by only albumin in 
the present study with the full regression of the following model:  
Vd (ml) = 688000 * e 0.0759 * albumin 
CL (ml/min) = 5960 * (CCR/59) 0.741 
Our model presented with albumin did not identify relationship between 
degree of malnutrition and Vd of digoxin, so we reanalyzed this model by 
categorical variables (Table 5). By this analysis, PIBW, age and sex were 
found to be covariates that have a significant effect. However, compared 
with the base model, RSE was not improved as well as showing correlation 
so that those were not chosen for final covariates. The amount of 
uncertainty (RSE%) associated with estimation of the coefficient of this 
model (covariate; albumin): θ2, θ3 were 11.24%, 5.15%, respectively and for 
interindividual variability of Vd and CL were 45.74% and 23.56%, 
respectively. Vd tended to be decreased as albumin decrease. This shows 
that digoxin’s Vd is affected by nutritional status and severity of illness. 
Thereby it is more suitable to explain digoxin’s Vd as categorized albumin 
level reflects degree of malnutrition rather than albumin value. As NRI 
decreases (<97.5), it also tended to have an influence on Vd. This shows that 
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digoxin’s Vd is affected by nutritional risk. In other words, it is showed that 
digoxin’s Vd is affected by the risk of malnutrition and severity of 
malnutrition and illness, which are expressed as NRI and albumin. The 
relationship between degree of malnutrition (albumin), nutritional risk (NRI) 
and Vd was described by the full regression of the following models:  
Vd (ml) = 788000*(EXP(0.019)*B))*(EXP(0.106)*C))*(EXP(0.219)*D)) 
CL (ml/min) = 5790*(CCR/59)** 0.739 
 
Vd (ml) = 
 832000*(EXP(-0.265)*B))*(EXP(0.036)*C))*(EXP(0.643)*D))*(EXP(0.02)*E)) 
CL (ml/min) = 5750*(CCR/59)** 0.710  
The bootstrap validation is performed as the determination of the stability 
and the evaluation of the performance of model. A total 1000 bootstrap 
samples was generated by repeated random sampling from the original data 
set. The final pharmacokinetic model was fitted repeatedly to the 1000 
bootstrapped samples. The parameter estimates of the final model using the 
original data set and the median parameter estimates and 95% confidence 
intervals obtained from bootstrap replications with successful runs (both 
estimation and covariate step were successfully converged) are shown in 
Table 6. The 95% confidence interval from bootstrap included the parameter 
values of the final model. The accuracy of pharmacokinetic model was 
acceptable according to the reasonably close agreement between 
corresponding pairs of bootstrap and final model parameters. 
The diagnostic plots of predicted versus observed concentrations indicated 
adequacy of the derived NONMEM model. Scatterplot between pairs of 
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measured concentration and predicted concentration obtained from base 
model (without covariate) was compared with final model (Figure 2). The 
final model is proven to be improved as the scatter plot of the identity line 
appears together with the narrow gap and scattered points that used to be 
far from the identity line have been reduced. Figure 3 shows weighted 
residual versus predicted concentration obtained from the base model was 
compared with the final model. The scatterplot of the final model indicated 
an improvement in much closer to the line of identity. This suggests that the 





This study was the first to identify the relationship between nutritional 
factors such as albumin, NRI and volume of distribution of digoxin in Korean 
patients with NONMEM. 
Digoxin exhibits a narrow therapeutic index and large inter/intra-patient 
variability in the disposition, which requires that the doses be carefully 
adjusted to an individual patient’s needs for minimizing digoxin toxicity. It 
would be helpful to understand the effect of various clinical factors on the 
pharmacokinetics of digoxin. These can be assessed by the population 
pharmacokinetic analysis of digoxin. The demographic factors are critical 
factors to the impacts on pharmacokinetic parameters of digoxin. Especially, 
nutritional status including malnutrition considerably influence on the 
absorption, plasma protein binding, distribution, biotransformation and 
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excretion of drugs. Generally, the major pathophysiological changes in 
malnutrition related to drug disposition are alterations of drug-protein 
binding.20 These were focused on measuring various proteins quantitatively. 
The binding of digoxin to plasma proteins is independent of concentration 
over a wide range and only 20 to 25% of digoxin is bound to plasma 
proteins.21 Albumin is important binding protein. Among the various 
nutritional parameters proposed, serum albumin is a good marker of 
nutritional status and visceral protein stores.22 Therefore, we analyzed in 
different perspectives with albumin, not as a drug-binding protein but a 
nutritional factor. Albumin was the significant covariate of Vd in the final 
model and was proven to have an impact according to degree of malnutrition 
through categorical variables analysis. The estimated effect of albumin is 
0.019 (if albumin < 2.8 mg/dl, B=1, C,D=0), 0.106 (if 2.8-3.5 mg/dl, C=1, 
B,D=0), 0.219 (if > 3.5 mg/dl, D=1, B,C=0) and this was expressed as the 
exponential value on Vd of digoxin. We came into conclusion that digoxin’s 
Vd was reduced more at the lower level of albumin with poor nutritional 
status and serious illness. 
About half of the total body digoxin load is bound to skeletal muscle, 
whereas only 1% is in the circulation.21 Although the concentration of digoxin 
in skeletal muscle is low compared with myocardial tissue, it is the single 
largest pool in the body because of the total body skeletal muscle mass.23 
The binding capacity of the skeletal muscle pool is 52-fold higher than that 
of the heart ventricular muscle pool. When analyzed in tissue obtained 
intraoperatively and at postmortem, digoxin is highly distributed into muscle, 
with lesser amounts in plasma & other body constituents.23 Therefore, small 
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changes in the fraction bound to skeletal muscle could profoundly affect the 
concentration of the drug in serum. The somatic protein status as 
represented the weight is equivalent to the skeletal muscle mass which 
declines in response to malnutrition or catabolic conditions.11 As assumed in 
our study, if there were equal pattern of distribution, shortage weight in 
skeletal muscle tissue would result in the decline of digoxin’s distribution 
space. Therefore, we undertook an analysis of PIBW (percent of ideal body 
weight), NRI (Nutrition Risk Index) effects, it contained influences the 
degree and change of weight on Vd of digoxin. If NRI is less than 97.5, which 
identifies moderate or major nutritional risk, it has more influence on Vd 
(Table 5). The estimated effect of NRI expressed as the exponential value 
was -0.265 (NRI < 83.5), 0.036 (NRI < 83.5-97.5) and this shows that 
digoxin’s Vd is affected by the risk of malnutrition. In this study, we couldn’t 
find the impact of weight that is expressed as PIBW, but this resulted from 
the fact that there were no differences in nutritional status due to the 
characteristics of our patient group. Thereby it is more appropriate to 
explain the relationship between digoxin’s Vd and nutritional factors that 
reflect severity of illness rather than weight or PIBW itself. 
Digoxin is excreted predominantly in the urine as an unchanged drug and 
eliminated only small amount by hepatic metabolism. Principal elimination 
(57-80%) of digoxin takes place by renal excretion,
24 hence renal function of 
a patient reflected by the creatinine clearance (CCR) plays a major role in 
determining the clearance of digoxin. At present study, multiple linear 
regressions using all the potential covariates showed that CL significantly 
correlated with creatinine clearance (CCR). The final regression model 
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suggested that pharmacokinetic parameters of digoxin were influenced by 
creatinine clearance. In other studies, decrease in volume of distribution of 
digoxin in the case of patients with renal impairment has been reported.1,25 
Study by Reuning et al suggested possible explanations of the decrease in 
the volume of distribution of digoxin in renal failure are: (1) reduction of the 
tissue mass (e.g. skeletal muscle), (2) reduced digoxin binding to other 
organs than skeletal muscle.26-29 However, Jogestrand and Ericsson found 
that the ratio of biopsied skeletal muscle digoxin concentration to serum 
concentration was not significantly different in patients with renal failure 
than in subjects with normal renal function.27 A reduced tissue mass (e.g., 
skeletal muscle) because of chronic renal failure also did not seem to be an 
important factor. Renal dysfunction may also cause decreased binding of 
digoxin to tissues.30 But, our study showed that it was the decreased binding 
capacity of digoxin by skeletal muscle reduction, as represented poor 
nutritional status (albumin) and increased nutritional risk (NRI), that 
explained the apparent reduction of digoxin’s Vd regardless of renal function.  
With increasing aging, lean body mass tends to decrease, adipose tissue 
tends to increase, although overall total body weight tends to decrease. It is 
generally known that age influences digoxin distribution. This is mainly in 
relation to lean body mass, which decreases by approximately 20% from the 
ages of 20 to 70 years.10 A loss of skeletal muscle is common in older 
persons.30 The volume of distribution for digoxin reduces with age and 
possibly results in higher serum concentrations. This could also suggest 
another basis in explaining the effect of reduced skeletal muscle mass on the 
Vd of digoxin. Subjects of our study included many older people, but we 
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didn’t find out any significant effect of age on the pharmacokinetic 
parameters of digoxin by demographic characteristic compromised of their 
good nutritional status. In addition to, we could not choose an age as 
covariate in categorical analysis by observed the correlation. Hence, further 
studies are necessary to conclusively determine the effects of age on 
pharmacokinetic parameters of digoxin, ideally containing various subgroup 
age. 
Conventional compartmental analysis of digoxin levels has reported a two-
compartment model in healthy adults.24 However, population analysis of 
sparse data has found a one-compartment model adequate for explaining the 
pharmacokinetics of digoxin.12 Because of the limited sampling strategy that 
we used in the therapeutic drug-monitoring laboratory, this study also 
decided the performance of population pharmacokinetic analysis in the light 
of a single-trough screening to digoxin concentration. Furthermore, one-
compartment model was easy application for therapeutic drug monitoring 
service in the clinical practice. Population analysis of digoxin in other studies 
done using NONMEM.13-15 The observed differences might be due to 
different disease severity, population size, ethnic differences, age and/or the 
method of population analysis. Population pharmacokinetics of digoxin has 
been reported in a Korean patient population (n=15).31 However, this study 
used a nonparametric expectation procedure, for the population modeling. In 
this method, no distribution model was assumed for interpatient variability 
and the error model. 
Multiple factors should be considered for digoxin dosage adjustment, as 
other drug interactions, effects of absorption in gastrointestinal disease, and 
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other intensive care environments exist. Therefore, the sum of the effects of 
these covariates on digoxin cannot be predictable. Not only monitoring of 
digoxin concentration but also patient’s clinical status and drug toxicity 
should be accomplished. Pharmacokinetic parameters of drug tend to be 
altered especially among the special populations such as the pediatric group, 
advanced age and physiologic change of malnutrition. The present study 
showed not only that digoxin’s Vd is related to nutritional factors   such as 
albumin and NRI but also Vd is affected by the degree of those factors 
represented the severity of illness and reduction of lean body mass. As 
proved in the study, it is well-known that digoxin’s PK is affected by 
malnutrition and severity of illness. However, it is meaningful enough to 
make sense that this study analyzed the degree of malnutrition and the 
degree of nutritional risk more specifically by assuming there is a 





This population pharmacokinetic model of digoxin by presented nutritional 
factors was developed for the first time with the NONMEM in Korean 
patients. The present study established important sources of variability in 
digoxin pharmacokinetics. Clinical application of this model may help 
calculate digoxin dose requirements according to degree of malnutrition 
affecting digoxin volume of distribution, and it will also be useful for 
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Table 1. Demographic data of the patients 
Characteristics  
Number of patients 108 
Number of samples  287 
Samples per patients (mean) 2.65 
Gender (n(%))  
    Male  58 (53.7) 
    Female  50 (46.3) 
Age (years, mean±SDa) 72.8 ± 13 
Weight (kg, mean±SD) 57.29 ± 11.99 
Percent of ideal body weight (mean±SD) 100.08 ± 17.21 
Digoxin dose (mg/day, mean±SD) 0.135 ± 0.054 
Serum digoxin concentration (mcg/L) 0.859 ± 0.384 
Indications (n(%))  
    Heart failure 36 (33.3) 
    Atrial fibrillation 56 (51.9) 
    Othersb 16 (14.8) 
Creatinine clearancec (ml/min, mean±SD) 59.32 ± 24.7 
Serum potassium (mmol/L, mean±SD) 4.3 ± 0.6 
Serum albumin (g/dl, mean±SD) 3.4 ± 0.54 
Serum cholesterol (mg/dl, mean±SD) 147.8 ± 40.43 
TLCd (cells/mm3, mean±SD) 1543.34 ± 915.78 
NRIe (mean±SD) 92.58 ± 8.33 
a Standard deviation 
b Cor-pulmonale (4), myocardial infarction (2), ventricular septal defect (7), post-operation (3) 
c Estimating creatinine clearance (CLCR) by the Cockcroft and Gault method
 
d Total lymphocyte count  = [white blood cell × % lymphocyte]/ 100 
e Nutritional risk index = [1.519 × serum albumin(mg/dl)] + 41.7 × [present / UBW(kg)] 
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Table 2. NONMEM output of base model 
Parameter 
Final Parameter Estimate 
Population mean %RSE IIV (%CV) %RSE 
Ka (hr-1) 3a - - - 
Vd (ml) 93800 15.45 40 68.75 
CL (ml/min) 4830 6.9 52.2 20.32 
a Fixed value 
RSE= relative standard error, IIV = interindividual variability, CV = coefficient of variation 




















Table 3. Preliminary screening of covariates by ADVAN2 TRANS2: effect on  
objective function value changing of addition of significant  
covariates in the base model 
Hypothesis Equation OFV LRT p-value Conclusion 
Base model 
 (ADVAN2 TRANS2) 
Ka = θ1(fixed 3) 
Vd = θ2 
CL = θ3 
-262.876    
Vd (volume of distribution) 
Did NRI influence Vd? 
   
θ2*NRI**θ4 -263.511 -0.635 >0.05 No 
θ2+NRI*θ4 -263.358 -0.482 >0.05 No 
Did albumin influence 
Vd? 
θ2*ABM**θ4 -264.274 -1.398 >0.05 No 
θ2+ABM*θ4 -263.803 -0.927 >0.05 No 
θ2*(EXP(θ4)*ABM) -263.463 -0.587 >0.05 No 
Did creatinine clearance  
influence Vd? 
θ2*CCR**θ4 -294.524 -31.648 <0.001 Yes 





θ3*CCR**θ5 -339.909 -77.033 <0.001 Yes 
θ3*(CCR/59)**θ5 -339.909 -77.033 <0.001 Yes 
θ3+CCR*θ5 -334.662 -71.786 <0.001 Yes 
OFV = objective function value; Ka = absorption rate constant; LRT = Likelihood ratio test 











Table 4. Continous variables analysis as the final model in Korean population  
Pharmacokinetic parameters for digoxin 
Hypothesis Equation OFV LRT Estimation Conclusion 
Base model 
 (ADVAN2 TRANS2) 
Ka = θ1(fixed 3) 
Vd = θ2, CL = θ3 
-262.876    
Did NRI influence 
Vd? 
Did creatinine 




-341.527 -78.651 FO Yes 








θ1 Absorption rate constant Fixed 3.0 - - 
θ2 Volume of distribution 11500 43900 381.74 
θ3 Clearance  5940 305 5.13 
θ4 Coefficient of NRI in Vd 0.963 0.849 88.16 
θ5 Coefficient of CCR in CL 0.744 0.13 17.47 
ω2Vd Interindividual variability (CV%) 
 in Vd 
0.303 (55) 0.125 41.25 
ω2CL Interindividual variability (CV%) 
 in CL 
0.158 (39.74) 0.0383 24.24 
σ2 Intraindividual variability (CV%) 0.0552 (23.5) 0.00869 15.74 
 
 
Did albumin  
influence Vd? 
Did creatinine 




-340.534 -77.658 FO Yes 










θ1 Absorption rate constant Fixed 3.0 - - 
θ2 Volume of distribution 688000 153000 22.23 
θ3 Clearance  5960 299 5.02 
θ4 Coefficient of ABM in Vd 0.0759 0.0686 90.38 
θ5 Coefficient of CCR in CL 0.741 0.128 17.27 
ω2Vd Interindividual variability (CV%) 
 in Vd 
0.299 (54.7) 0.148 49.50 
ω2CL Interindividual variability (CV%) 
 in CL 
0.155 (39.37) 0.0368 23.74 










-344.7 -81.824 FO Yes 








θ1 Absorption rate constant Fixed 3.0 - - 
θ2 Volume of distribution 101000 59500 58.99 
θ3 Clearance  5990 309 5.16 
θ4 Coefficient of CCR in Vd 0.561 0.14 24.96 
θ5 Coefficient of CCR in CL 0.644 0.119 18.48 
ω2Vd Interindividual variability (CV%)  
in Vd 
0.423 (65) 0.147 34.75 
ω2CL Interindividual variability (CV%) 
 in CL 
0.162 (40.24) 0.032 19.75 







OFV = objective function value; Ka = absorption rate constant; LRT = Likelihood ratio test; 
FO = First-order estimation method; FOCE = First-order conditional estimation 
SE= standard error; RSE= Relative standard error (RSE%=SE/value*100) 
ABM= serum albumin, Vd= volume of distribution (ml), CCR= creatinine clearance, CL= 
























Table 5. Categorical variables analysis in Korean population pharmacokinetic  
parameters for digoxin 
Parameter 
Final parameter estimate 
Population mean %RSE* IIV(%CV) %RSE* 
CL (ml/min) 5790 5.15 41.23 23.56 
Effect of CCR 0.739 16.1   
Vd (ml) 788000 11.24 54.25 45.74 
Effect of albumin 0.019/0.106/0.219    
RV (%CV) 0.0575  24.33 15.13 
CL (ml/min) 5750 4.9 41.38 21.83 
Effect of CCR 0.710 13.96   
Vd (ml) 832000 12.14 53.78 60.63 
Effect of NRI -0.265/0.036/0.643/0.02    
RV (%CV) 0.0528  23.28 15.98 
CL (ml/min) 5760 4.8 40.66 23.79 
Effect of CCR 0.743 15.34   
Vd (ml) 605000 42.81 59.94 44.95 
Effect of PIBW 0.472/0.072/0.415/0.424    
RV (%CV) 0.0549  23.75 16.81 
CL (ml/min) 5830 4.8 40.80  
Effect of CCR 0.727 15.68  22.4 
Vd (ml) 819000 83.88 56.84  
Effect of sex 0.172/-0.0678   43.75 
RV (%CV) 0.0569  24.19 15.62 
CL (ml/min) 5810 7.78 40.66 25.42 
Effect of CCR 0.748 18.18   
Vd (ml) 813000 610 59.83 47.38 
Effect of age 0.0624/0.098    
RV (%CV) 0.0568  24.17 15.44 
*
Relative standard error (RSE%=SE/value*100) 
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Random-effects models : Vd = TVVd * EXP(θ2), CL = TVCL * EXP(θ3) 
Where, CL = clearance (ml/min), Vd= volume of distribution (ml), CCR= creatinine clearance, 
CV%= coefficient of variation, PIBW = percent of ideal body weight, NRI = nutritional risk index 
@ Categorical variables range : a = albumin (mg/dL) < 2.8, 2.8~.3.5, >3.5   
                             b = NRI < 83.5, 83.5~97.5, 97.5~100, > 100 
                             c = PIBW (%) ≥ 69, 70~79, 80~89, ≤ 90 
                             d = sex ; male, female 






















Table 6. Population pharmacokinetic parameters from final model and  
bootstrap validation 
Parameter 




Medians 95% Confidence Interval 
Continous variable model 
Vd (ml) 688000 153000 605000 230975 944050 
Effect of ABM 0.0759 0.0686 0.115 0.00902 0.42705 
CL (ml/min) 5960 299 5900 5339 6480 
Effect of CCR 0.741 0.128 0.7605 0.50495 1.02 
Categorical variable model 
Vd (ml) 788000 88600 798500 505275 1109250 
Effect of ABM 0.019 0.0128 0.00901 -0.16385 0.08958 
 0.106 0.0764 0.09945 -0.26085 0.44963 
 0.219 0.164 0.1985 -0.459175 0.65248 
CL (ml/min) 5790 298 5780 5210 6400 
Effect of CCR 0.739 0.119 0.7355 0.50553 0.398385 
*obtained from the original data 
#Mean calculated from 1000 bootstrap 






























Figure 2. Comparison of scatterplot of measured concentration versus  







Figure 3. Comparison of scatterplot of weight residuals versus predicted  








입원 환자들에서 안전하고 효과적인 디곡신의 투여를 위해서는 약물의 
체내 동태와 이에 영향을 미치는 다양한 요인들의 영향을 아는 것이 
필요하다. 하지만, 이러한 영향 요인들에 대한 연구들은 개인별 영양 
상태와 디곡신의 요구량에 대한 관계를 밝히고자 시도하였던 적이 없다. 
이에 본 연구에서는 한국 입원 환자들을 대상으로 디곡신의 약동학을 
예측하고 이러한 다양성에 영향을 미치는 요인 중 영양 상태와의 관계를 
규명하고자 하는 것을 목적으로 하였다. 
분당서울대학교병원에서 경구로 디곡신을 투여 받은 106명(255개의 
혈중 농도)의 치료 농도 모니터링 결과를 후향적으로 검토하였다. 
디곡신의 약동학은 비선형 혼합효과 모델링을 이용하여 1-구획 약동학적 
모델과 다중 최저농도 접근법으로 분석하였다. 
환자들의 개별 특성과 생화학적, 영양학적 지표를 공변량으로 보고 
다양한 관계를 탐색하였다. 비선형 혼합효과 모델링에 의해 측정된 
디곡신의 청소율은 신기능, 혈중 포타슘 농도, 연령과 이상 체중비에 
영향을 받았다. 이러한 영향은 다음과 같은 식으로 나타낼 수 있다. CL/F 
(L/h) = 1.36× (CCR/50)1.580 × K0.835 × 0.055× (AGE/65) × 
(PIBW/100)0.403 청소율에 대한 개체내 다양성(CV)은 34.3%였고 관찰 
농도와 예측 농도 사이의 잔차 다양성(SD)은 0.225 µg/L였다. 
부트스트랩을 통한 중앙값은 비선형 혼합효과 모델링의 측정치 5%내에 
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있으므로 본 모델의 예측이 적절함을 입증할 수 있다. 또한, 다른 
실험군을 통한 상관성 분석을 통해서도 관찰치와 본 모델을 적용한 
예측치 사이에 선형 상관성이 있음을 밝힘으로서 그 유효성을 
입증하였다. 
디곡신의 일상적인 치료 농도 모니터링에 본 모델을 적용하기 
위해서는 이 연구와 동일한 조건의 환자군을 만족해야 할 것이므로 좀 
더 다양한 영양 상태의 효과들을 입증하기 위한 전향적 약동학적 
연구들이 필요하겠다. 
본 연구는 디곡신의 약동학적 다양성을 설명함에 있어 영양 상태라는 
중요한 변수를 확립하였다는 것에 큰 의의가 있으며 이로서 한국 입원 
환자에서 약동학적 모수들과 영양 상태와의 관계를 보여주었다.  
주요어 : 디곡신, 비선형 혼합효과 모델, 집단 약동학, 영양 상태 













드디어 이 감사의 글을 쓰면서 한동안 큰 숙제였던 박사논문에 마침표를 찍고 
있습니다. 
이 논문이 완성되기까지 언제나 묵묵히 기다려주시며 격려해주신 신완균교수님 
감사 드립니다. 약학을 선택하고 병원에서 임상을 공부하고 수많은 업무를 
하면서 가장 큰 인생의 열쇠를 제게 주셨습니다. 사회에 첫발을 내딛고 묵묵히 
열심히 하는 것이 제일인 줄만 알았던 제게 먼저 손을 내밀어 주시고 항상 
따뜻하게 인도해주셨던 이병구교수님 감사 드립니다. 병원 업무를 하면서 
열심히 하였다고 너그럽게 논문 심사해주신 이명걸교수님, 오정미교수님, 
김은경교수님, 김대덕교수님 감사 드립니다. 
학교를 마치며 무엇을 해야 할 지 아니 하고 싶은지를 모른 채 언니의 권유로 
시작한 서울대병원에서의 인턴, 레지던트 생활은 제 인생에 큰 나침반이 되는 
시간이었습니다. 하루하루가 즐겁고 앎에 대한 기쁨으로 순식간에 지나가버린 
2년은 앞으로 계속 임상약학을 해야겠다는 내 인생의 소명처럼 느껴지며 
자연스레 시작된 병원약사의 길을 안내하였습니다. 다양한 임상 업무를 해내는 
내내 많은 갈증이 있었고 여러 가지 시험에도 도전하게 되었지만 무엇보다 
학교에서 정식으로 학위를 마치고 좀 더 이 분야의 전문가로서 떳떳하고자 
시작한 학업이었습니다. 이제 마무리를 짓고 큰 숙제 하나를 해내는 오늘이지만 
한편, 그 동안 병원 업무에 밀려 제대로 하지 못했던 학위논문을 병원을 
그만두고 나서야 완성할 수 있어서 스스로의 부족함에 아쉬움이 남는 
순간입니다. 
이 논문을 쓰기 시작하였던 곳인 분당서울대병원 식구들에게 감사의 말을 
85 
 
전합니다. 이제 곧 병원을 그만 둔지도 1년이 되어가지만 여전히 갈 때마다 
이곳이 친정이라며 따뜻하게 맞아주시는 이은숙 부장님 항상 불평과 불만이 
많았던 저에게 끝까지 웃으면서 격려해주셨던 것 잊지 않겠습니다. 감사합니다. 
언제나 할말 많은 주임약사를 데리고 일하시느라 고생하셨던 이정화팀장님, 
남궁형욱팀장님, 최경숙팀장님 역시 감사 드립니다. 사실 병원 식구들 일일이 
나열하고 싶은 사람들이 너무 많지만 하나하나 나열하지 못함을 이해하여 주기 
바랍니다. 언제나 잘한다며 격려해주었던 선배약사님들, 내가 있어서 힘이 
난다던 후배약사님들(특히, 숙, 홍), 사실 언제나 제가 그들 때문에 힘이 
났었습니다. 마지막까지 동고동락을 같이했던 외래약국 식구들 모두 모두 
감사합니다. 이것으로 인연은 끝이 아니라 시작으로 생각하며 항상 도움이 되는 
선배약사가 또 후배약사가 되겠습니다. 
이 논문을 마무리 지었던 곳인 임상약학실 선후배에게도 감사의 말을 전합니다. 
작년 8월 갑자기 나타나 책상 하나 자리잡고 앉아서 도움도 못되고 있을 때 
매일 따뜻한 얼굴로 맞아주고 오히려 챙겨주었던 고마운 식구들, 제가 온 것이 
오히려 든든하다고 힘주셨던 류윤미선생님, 가끔 마주쳐도 환하게 인사해주시던 
강병철선생님, 무엇이든지 물어봐도 좋았던 최청암, 슬그머니 신경 써주는 
이정윤, 꿋꿋이 열심히 하는 모습을 오히려 배우고 싶었던 정옥분, 함께 한 
시간은 짧지만 항상 반겨주었던 김정아, 타지에 와서 너무 열심히 하는 모습에 
반하게 했던 김은혜, 혼자서도 무엇이든 잘하는 긍정의 아이콘 공지선, 병원 
다니면서 열심히 석사 마무리 지은 윤한샘, 오랜만에 온 연건동에서 무엇보다 
낯설지 않아 반가웠던 최정윤 이외에도 김아정선생님, 문미라선생님, 
김은아선생님 모두모두 감사 드립니다. 
언제나 멀리서 응원해주는 후배 민경이, 병원을 그만두어도 항상 먼저 연락하며 
힘이 되어주는 여러 후배약사들 모두가 생각납니다. 매번 전화로 메일로 
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이것저것 물어보는데도 항상 친절히 답해주었던 휘열군(윤박사님)에게 누구보다 
고맙다고 전하고 싶습니다. 
이 세상에 태어나 오늘의 제가 있게 해준 가족들, 언제나 저의 기쁨과 슬픔을 
함께 해주었기에 하루하루 버틸 수 있었습니다. 둘째 딸이 하는 거라면 뭐든지 
믿고 이해해주신 부모님 감사 드리며 이 논문을 부모님께 바칩니다. 앞으로 
더욱 열심히 사는 훌륭한 약사가 되어 부모님의 은혜에 꼭 보답하겠습니다. 
무엇보다 같은 약사로서 많은 고민을 함께 나눌 수 있어서 좋았던 우리 
수임언니, 나의 멘토로 항상 함께 해주어 너무 고맙고 나보다 더 속상해 해주고 
화내주어서 언니 때문에 힘을 낼 수 있었던 것 같습니다. 우리 언니는 잘할 수 
있다며 무조건 믿어주는 셋째 동생 안나, 이제는 언니가 무조건 믿어주겠다고 
얘기하고 싶습니다. 혼자서 먼 미국에서 악착같이 공부해서 열심히 그리고 
멋지게 해내고 있는 우리 막냉이 선정, 언니가 오히려 배울 점이 많은데도 항상 
언니 최고라고 해주어서 너무 고맙습니다. 또한, 내 인생의 새로운 식구들, 
언제나 연구도 진료도 게을리하지 않으며 저에게 모범을 보여주시는 우리 형부, 
세상에서 이모가 가장 사랑하는 우리 조카 승준이, 채빈이 그 존재만으로도 
감사 합니다. 
이렇게 감사의 글을 쓰는 순간에도 참 부끄럽다는 아직 많이 부족하다는 생각을 
합니다. 이제야 겨우 내가 아는 것들을 연구해 보고자 하는 마음도, 요령도, 
자신감도 생긴 것 같아 이 논문은 무엇보다 제 인생에서 새로운 출발을 다짐케 
하는 시작인 것 같습니다. 이 다짐을 잊지 않고 앞으로 더욱 열심히 연구하고 
공부하는 약사로 평생 살겠습니다. 다시 한번 엄마, 아빠, 언니, 동생들, 형부, 
조카들, 나의 가족에게 사랑한다고 고맙다는 말을 가슴 깊이 전합니다. 
 
 
